Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR

NMR in Biomedicine

Volumn 22, Issue 4, 2009, Pages 456-461

  Gabellieri, Cristina ^a   Beloueche Babari, Mounia ^a   Jamin, Yann ^a   Payne, Geoffrey S ^a   Leach, Martin O ^a   Eykyn, Thomas R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

31P NMR; Choline kinase; Enzymatic assy; H 89; Hemicholinium 3

Indexed keywords

31P NMR; CHOLINE KINASE; ENZYMATIC ASSY; H-89; HEMICHOLINIUM-3;

AMINES; CELL MEMBRANES; ENZYMES; REACTION RATES;

NUCLEAR MAGNETIC RESONANCE;

CHOLINE KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; HEMICHOLINIUM 3; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHORYLCHOLINE; ISOQUINOLINE DERIVATIVE; PHOSPHORUS; SULFONAMIDE;

ARTICLE; CANCER CELL; CANCER RESEARCH; CELL LYSATE; ENZYME ACTIVITY; ENZYME MECHANISM; HELA CELL; HUMAN; HUMAN CELL; MEASUREMENT; MEMBRANE TRANSPORT; MODULATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

CELL LINE, TUMOR; CHOLINE KINASE; HUMANS; ISOQUINOLINES; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; PHOSPHORUS ISOTOPES; PHOSPHORYLATION; SULFONAMIDES; TIME FACTORS;

EID: 67649224040     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1361     Document Type: Article

References (34)

1. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
2. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol. Pharmaceutics 2006; 3: 496-506.
3. Ronen SM, Rushkin E, Degani H. Lipid-metabolism in T47d human breast-cancer cells - P-31 and C-13-NMR studies of choline and ethanolamine uptake. Biochim. Biophys. Acta 1991; 1095: 5-16.
4. de Molina AR, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez JJ, Bonilla F, Rosell R, Lacal JC. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 2002; 296: 580-583.
5. de Molina AR, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21: 4317-4322.
6. Tadokoro K, Ishidate K, Nakazawa Y. Evidence for the existence of isozymes of choline kinase and their selective induction in 3-methylcholanthrene-treated or carbon tetrachloride-treated rat-liver. Biochim. Biophys. Acta 1985; 835: 501-513.
7. Ratnam S, Kent C. Early increase in choline kinase-activity upon induction of the H-ras oncogene in mouse fibroblast cell-lines. Arch. Biochem. Biophys. 1995; 323: 313-322.
8. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br. J. Cancer 2001; 84: 691-696.
9. Al-Saffar NMS, Troy H, de Molina AR, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006; 66: 427-434.
10. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr. Pharm. Des 2003; 9: 891-902.
11. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, Zweit J. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesistesting clinical trials of innovative therapies. J. Natl. Cancer Inst. 2006; 98: 580-598.
12. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interferencemediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005; 65: 11034-11043.
13. Rosch P. NMR-studies of phosphoryl transferring enzymes. Prog. Nucl. Magn. Reson. Spectrosc. 1986; 18: 123-169.
14. 31P NMR spectroscopy. J. Biol. Chem. 1987; 262: 14875-14878.
15. Brindle KM. NMR methods for measuring enzyme kinetics in vivo. Prog. Nucl. Magn. Reson. Spectrosc. 1988; 20: 257-293.
16. Hamza M, Lloveras J, Ribbes G, Soula G, Dousteblazy L. An invitro study of hemicholinium-3 on phospholipid-metabolism of Krebs-II ascites cells. Biochem. Pharmacol. 1983; 32: 1893-1897.
17. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001; 4: 419-426.
18. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc. Drug Rev. 2006; 24: 261-274.
19. Wieprecht M, Wieder T, Geilen CC. N-[2-bromocinnamyl(amino) ethyl]- 5-isoquinolinesulphonamide (H-89) inhibits incorporation of choline into phosphatidylcholine via inhibition of choline kinase and has no effect on the phosphorylation of CTP: phosphocholine cytidyltransferase. Biochem. J. 1994; 297: 241-247.
20. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005; 65: 9369-9376.
21. Malito E, Sekulic N, Too WCS, Konrad M, Lavie A. Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine. J. Mol. Biol. 2006; 364: 136-151.
22. Spanner S, Ansell GB. Choline kinase and ethanolamine kinase- activity in the cytosol of nerve-endings from rat forebrain. Biochem. J. 1979; 178: 753-760.
23. 2+] using P-31 NMR. J. Biol. Chem. 1996; 271: 21142-21150.
24. 2+]: theoretical and practical problems. NMR Biomed. 1999; 12: 217-220.
25. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000; 351: 95-105.
26. Michel V, Yuan ZF, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp. Biol. Med. 2006; 231: 490-504.
27. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59: 80-84.
28. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton NMR spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61: 3599-360
29. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004; 64: 4270-4276.
30. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer. 2007; 120: 1721-1730.
31. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett. 2000; 161: 207-214.
32. Gabellieri C, Reynolds S, Lavie A, Payne GS, Leach MO, Eykyn TR. Therapeutic target metabolism observed using hyperpolarized 15N choline. J. Am. Chem. Soc. 2008; 130: 4598-4599.
33. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996; 16: 1375-1379.
34. Hara T, Bansal A, DeGrado TR. Choline transporter as a novel target for molecular imaging of cancer. Mol. Imaging 2006; 5: 498-509.